Boon Chuan Low

Prof. Boon Chuan Low

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2014 in FEBS Letters
Verified
Journal Article
Open access
BLBoon Chuan Low
Boon Chuan Low
CPCatherine Qiurong Pan
Catherine Qiurong Pan
GSG.V. Shivashankar
G.V. Shivashankar
ABAlexander Bershadsky
Alexander Bershadsky
MSMarius Sudol
Marius Sudol
MSMichael Sheetz
Michael Sheetz
Organ size is controlled by the concerted action of biochemical and physical processes. Although mechanical forces are known to regulate cell and tissue behavior, as well as organogenesis, the precise molecular events that integrate mechanical and biochemical signals to control these processes are not fully known. The recently delineated Hippo‐tumor suppressor network and its two nuclear effectors, YAP and TAZ, shed light on these mechanisms. YAP and TAZ are proto‐oncogene proteins that respond to complex physical milieu represented by the rigidity of the extracellular matrix, cell geometry, cell density, cell polarity and the status of the actin cytoskeleton. Here, we review the current knowledge of how YAP and TAZ function as mechanosensors and mechanotransducers. We also suggest that by deciphering the mechanical and biochemical signals controlling YAP/TAZ function, we will gain insights into new strategies for cancer treatment and organ regeneration.

1 May 2017 in Cell Reports
Verified
Journal Article
Open access
YQYiting Qiao
Yiting Qiao
JCJianxiang Chen
Jianxiang Chen
YLYing Bena Lim
Ying Bena Lim
Megan Finch-EdmondsonMegan Finch-Edmondson
Megan Finch-Edmondson
VSVeerabrahma Pratap Seshachalam
Veerabrahma Pratap Seshachalam
MSMarius Sudol
Marius Sudol
Yes-associated protein (YAP) is regulated by mechanical cues via the interaction of the Hippo pathway with cytoskeleton. Previous studies showed that YAP plays a role in regulating the actomyosin network by suppressing Rho GTPase in medaka fish. Here, we identify Rho GTPase activating protein 29 (ARHGAP29) as a transcriptional target of YAP in a human gastric cancer cell line. YAP promotes the expression of ARHGAP29 to suppress the RhoA-LIMK-cofilin pathway, destabilizing F-actin. The overexpression of YAP causes cytoskeletal rearrangement by altering the dynamics of F-actin/G-actin turnover, thus promoting migration. In a mouse model, circulating tumor cells (CTCs) exhibit an increased ARHGAP29 RNA level compared with cells at primary tumor sites, and the metastatic potential of CTCs is positively correlated with ARHGAP29 expression. Moreover, increased ARHGAP29 expression is correlated with shortened survival of human gastric cancer patients. Our study provides a model to understand YAP's contribution to cancer metastasis via regulation of actin dynamics.

26 April 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
KTK. Thangavelu
K. Thangavelu
CPCatherine Qiurong Pan
Catherine Qiurong Pan
TKTobias Karlberg
Tobias Karlberg
GBGanapathy Balaji
Ganapathy Balaji
MUMahesh Uttamchandani
Mahesh Uttamchandani
JSJayaraman Sivaraman
Jayaraman Sivaraman
Besides thriving on altered glucose metabolism, cancer cells undergo glutaminolysis to meet their energy demands. As the first enzyme in catalyzing glutaminolysis, human kidney-type glutaminase isoform (KGA) is becoming an attractive target for small molecules such as BPTES [bis-2-(5 phenylacetamido-1, 2, 4-thiadiazol-2-yl) ethyl sulfide], although the regulatory mechanism of KGA remains unknown. On the basis of crystal structures, we reveal that BPTES binds to an allosteric pocket at the dimer interface of KGA, triggering a dramatic conformational change of the key loop (Glu312-Pro329) near the catalytic site and rendering it inactive. The binding mode of BPTES on the hydrophobic pocket explains its specificity to KGA. Interestingly, KGA activity in cells is stimulated by EGF, and KGA associates with all three kinase components of the Raf-1/Mek2/Erk signaling module. However, the enhanced activity is abrogated by kinase-dead, dominant negative mutants of Raf-1 (Raf-1-K375M) and Mek2 (Mek2-K101A), protein phosphatase PP2A, and Mek-inhibitor U0126, indicative of phosphorylation-dependent regulation. Furthermore, treating cells that coexpressed Mek2-K101A and KGA with suboptimal level of BPTES leads to synergistic inhibition on cell proliferation. Consequently, mutating the crucial hydrophobic residues at this key loop abrogates KGA activity and cell proliferation, despite the binding of constitutive active Mek2-S222/226D. These studies therefore offer insights into ( i ) allosteric inhibition of KGA by BPTES, revealing the dynamic nature of KGA's active and inhibitory sites, and ( ii ) cross-talk and regulation of KGA activities by EGF-mediated Raf-Mek-Erk signaling. These findings will help in the design of better inhibitors and strategies for the treatment of cancers addicted with glutamine metabolism.

16 September 2002 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
EWEsther Sook Miin Wong
Esther Sook Miin Wong
CFChee Wai Fong
Chee Wai Fong
JLJormay Lim
Jormay Lim
PYPermeen Yusoff
Permeen Yusoff
BLBoon Chuan Low
Boon Chuan Low
GGGraeme R. Guy
Graeme R. Guy
Drosophila Sprouty (dSpry) was genetically identified as a novel antagonist of fibroblast growth factor receptor (FGFR), epidermal growth factor receptor (EGFR) and Sevenless signalling, ostensibly by eliciting its response on the Ras/MAPK pathway. Four mammalian sprouty genes have been cloned, which appear to play an inhibitory role mainly in FGF‐ mediated lung and limb morphogenesis. Evidence is presented herein that describes the functional implications of the direct association between human Sprouty2 (hSpry2) and c‐Cbl, and its impact on the cellular localization and signalling capacity of EGFR. Contrary to the consensus view that Spry2 is a general inhibitor of receptor tyrosine kinase signalling, hSpry2 was shown to abrogate EGFR ubiquitylation and endocytosis, and sustain EGF‐induced ERK signalling that culminates in differentiation of PC12 cells. Correlative evidence showed the failure of hSpry2ΔN11 and mSpry4, both deficient in c‐Cbl binding, to instigate these effects. hSpry2 interacts specifically with the c‐Cbl RING finger domain and displaces UbcH7 from its binding site on the E3 ligase. We conclude that hSpry2 potentiates EGFR signalling by specifically intercepting c‐Cbl‐mediated effects on receptor down‐regulation.

21 June 2018 in Chemical Reviews
Verified
Journal Article
Closed access
PCParthiv Kant Chaudhuri
Parthiv Kant Chaudhuri
BLBoon Chuan Low
Boon Chuan Low
CLChwee Teck Lim
Chwee Teck Lim

1 November 2009 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
DKDaniel Kirilly
Daniel Kirilly
YGYing Gu
Ying Gu
YHYafen Huang
Yafen Huang
ZWZhuhao Wu
Zhuhao Wu
ABArash Bashirullah
Arash Bashirullah
FYFengwei Yu
Fengwei Yu